DNA To Deliver Safe Pregnancies: Seneca EIS Portfolio Company features in the FT

DNA To Deliver Safe Pregnancies: Seneca EIS Portfolio Company features in the FT


Technology to analyse tiny traces of DNA is now so sensitive that it can diagnose disease by detecting rogue mutations circulating in human blood. The most important future application of “cell-free DNA diagnosis”, as it is called, is likely to be in oncology — detecting cancer genes shed by tumours elsewhere in the body — but an early commercial use of the technique is in prenatal diagnosis of genetic disorders in the foetus.

Premaitha Health, based in Manchester, is the first European company to offer non-invasive prenatal testing of this sort. The test is much more accurate than the current technique, which requires sampling of foetal DNA from the womb or placenta, and which produces many false positive results.


To read more please visit The Financial Times (subscription required)

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.